HIV-Associated Psychosis and HIV-Associated Neurocognitive Disorder
HIV-associated psychosis means hallucinations, delusions or severe thought/behaviour disturbance occurring in a person living with HIV after primary psychiatric, substance-induced, medication-related, delirious and CNS causes have been assessed. HIV-associated neurocognitive disorder (HAND) describes cognitive impairment in which HIV-associated brain injury may contribute; severe impairment that interferes substantially with daily independence has historically been called HIV-associated dementia or AIDS dementia complex.
Never label acute confusion “HIV psychosis.” Fever, headache, neck stiffness, seizures, focal weakness, reduced consciousness, severe immunosuppression or rapid cognitive change requires urgent investigation for meningitis, cryptococcosis, cerebral toxoplasmosis, tuberculosis, neurosyphilis, malaria, metabolic illness, medicine toxicity and delirium.
Learning objectives
- Differentiate psychosis, delirium, depression and neurocognitive impairment in people living with HIV.
- Explain direct, opportunistic, treatment-related and psychosocial mechanisms.
- Plan staged medical, antiretroviral, psychiatric and nursing management.
Aetiology and pathophysiology
Direct and indirect mechanisms
- HIV-associated brain injury: HIV enters the CNS early through infected monocytes/macrophages. Chronic immune activation, inflammatory mediators, oxidative stress and neuronal network injury can impair attention, processing speed, executive function, learning and motor performance.
- Advanced HIV and opportunistic disease: cryptococcal meningitis, toxoplasmosis, TB meningitis/tuberculoma, progressive multifocal leukoencephalopathy, CMV disease and lymphoma may produce cognitive change, psychosis, seizures or focal signs.
- Systemic/metabolic illness: sepsis, hypoxia, anaemia, electrolyte disturbance, renal/hepatic failure and malnutrition cause delirium or worsen cognition.
- Medicines/substances: corticosteroids, some antiretroviral or anti-TB adverse effects, interactions, intoxication and withdrawal may alter mood, sleep or perception.
- Independent psychiatric illness: schizophrenia, bipolar disorder, severe depression, PTSD and substance-use disorders may precede or coexist with HIV.
Clinical manifestations
| Syndrome | Typical pattern | Distinguishing clues |
|---|---|---|
| Delirium | Acute fluctuating attention/awareness, disorientation, altered arousal, visual illusions/hallucinations | Medical emergency; usually physiological or toxic cause. |
| Psychosis | Delusions, auditory hallucinations, thought disorder, disorganized or catatonic behaviour | Attention and consciousness may be relatively preserved unless delirium coexists. |
| Depression | Low mood/anhedonia, guilt, hopelessness, sleep/appetite change, poor concentration | Psychomotor slowing may imitate cognitive disorder; assess suicide risk. |
| Neurocognitive impairment | Slowed thinking, poor attention, memory/learning and executive difficulty, reduced work or self-care capacity | Establish decline from baseline and functional impact; consider multiple causes. |
Assessment
- Immediate ABCDE: vitals, SpO₂, glucose, consciousness, seizure activity, dehydration and signs of sepsis or raised intracranial pressure.
- History: exact onset/course, headache/fever/seizures, focal symptoms, ART regimen/adherence, CD4/viral-load history where available, opportunistic infections, all medicines, substances, prior mental illness and baseline function.
- Collateral information: family or treatment supporter may clarify adherence, behaviour, function and timing, while confidentiality and consent are respected.
- Mental-state and cognition: appearance, speech, mood, thought, perception, attention, orientation, memory, executive function, insight and suicide/violence/vulnerability risk.
- Physical/neurological examination: meningism, fundus where skilled, cranial nerves, focal weakness, coordination, gait, sensory loss, oral/skin signs, wasting and medicine adverse effects.
Investigations and interpretation
- Basic tests: glucose, FBC, electrolytes, renal/liver function, malaria testing according to epidemiology and presentation; identify reversible physiological causes.
- HIV assessment: confirm status according to national testing algorithm if not documented; viral load, CD4 and ART history guide HIV control and opportunistic-disease risk.
- Infection work-up: blood cultures, cryptococcal antigen, TB and syphilis investigations according to presentation and immune status.
- Neurodiagnostics: brain imaging before lumbar puncture when focal deficit, papilloedema, markedly reduced consciousness or mass lesion is suspected. CSF testing is cause-directed and performed only when safe.
- Cognition: a brief screen identifies concern but education, language, depression, fatigue and acute illness affect performance; diagnosis requires clinical context and functional assessment.
Management
First hours
- Stabilize airway, oxygenation, glucose, circulation, temperature, seizures and severe agitation.
- Use infection precautions appropriate to suspected illness; create a quiet, observable environment and prevent falls, aspiration and self-harm.
- Collect indicated specimens without delaying time-critical antimicrobial treatment when meningitis/sepsis is suspected.
- Discuss urgently with HIV/medical/neurological and mental-health teams; transfer if imaging, CSF evaluation or high-dependency care is unavailable.
Cause-directed and HIV treatment
- Treat opportunistic infection according to current Uganda/WHO protocols. Regimens depend on diagnosis, pregnancy, renal/hepatic function and drug interactions.
- Start, continue or optimize antiretroviral therapy through an HIV clinician. Timing may need coordination with acute CNS infection to balance immune-reconstitution risk; never improvise ART interruption.
- Assess adherence barriers: stigma, cognitive impairment, adverse effects, cost/transport, depression, substance use and food insecurity. Use simplified reminders and a consented treatment supporter.
Psychiatric treatment
Use de-escalation and environmental treatment first. When antipsychotic medicine is required, start cautiously, select for interaction/metabolic/QT/EPS profile, and monitor consciousness, BP, ECG risk, movement disorder and metabolic effects. Avoid routine sedative polypharmacy in delirium. Treat depression and substance-use disorders while checking interactions and suicide risk.
| Medicine issue | Clinical importance | Nursing responsibility |
|---|---|---|
| Antipsychotics | May reduce dangerous/distressing psychosis but can cause EPS, NMS, hypotension, sedation, QT prolongation and metabolic effects. | Baseline vitals/weight and interaction review; monitor movement, temperature/rigidity, ECG risk, glucose/lipids and response. |
| ART interactions | Enzyme inhibition/induction can raise or lower psychotropic concentrations; overlapping QT, hepatic and metabolic toxicity may occur. | Reconcile every medicine, use current interaction checker/formulary and report toxicity or loss of efficacy. |
| Corticosteroids/anti-TB medicines | May contribute to insomnia, mood change or psychosis in susceptible patients. | Document temporal relationship; never stop essential therapy abruptly—obtain specialist review. |
Detailed nursing care plan
| No. | Intervention | Rationale and measurable evaluation |
|---|---|---|
| 1 | Monitor vitals, SpO₂, GCS/attention, pupils, focal signs, glucose, fluid balance and seizure activity at acuity-based intervals. | Detects CNS infection, raised intracranial pressure, sepsis or metabolic deterioration. Escalate new focal signs, falling consciousness or unstable observations immediately. |
| 2 | Use one calm communicator, simple orientation cues, consistent routine and least-restrictive safety observation. | Reduces fear and cognitive overload. Evaluate by reduced distress, improved cooperation and absence of avoidable injury. |
| 3 | Assess swallowing, nutrition, hydration, continence, mobility and skin; assist while preserving independence. | Cognitive and neurological impairment increases aspiration, malnutrition, falls and pressure-injury risk. |
| 4 | Administer ART, antimicrobials and psychotropics exactly as prescribed; check timing, interactions and adverse effects. | Consistent effective therapy treats causes and prevents resistance/toxicity. Document doses, tolerance and clinical response. |
| 5 | Protect confidentiality, use non-stigmatizing language and assess consent/capacity for each decision. | Maintains rights and treatment engagement; HIV status is not permission for unnecessary disclosure. |
| 6 | Prepare discharge tools: written/pictorial schedule, pill organizer where feasible, warning signs, appointments and treatment supporter with consent. | Compensates for executive/memory impairment and reduces relapse/readmission. |
Complications, rehabilitation and prevention
- Suicide, self-neglect, seizures, aspiration, falls, treatment interruption, exploitation and caregiver burnout require active prevention.
- Rehabilitation may include cognitive strategies, occupational therapy, graded activity, adherence support and social protection.
- Promote early HIV testing, sustained viral suppression, prevention/treatment of opportunistic infection, cardiovascular-risk control, nutrition, sleep, substance-risk reduction and regular mental-health/cognitive review.
Revision questions
- Differentiate delirium, HIV-associated psychosis, depression and neurocognitive disorder.
- Outline the investigation of new psychosis with fever and focal weakness in advanced HIV.
- Explain six antiretroviral–psychotropic nursing responsibilities.
- Develop measurable outcomes for impaired cognition and self-care.
References
- WHO. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring.
- WHO. mhGAP Guideline, 2023.
- Uganda Ministry of Health. Uganda Clinical Guidelines, 2023.
- International HIV-Cognition Working Group. Consensus recommendations on cognitive impairment in people living with HIV, 2023.